Terms: = Prostate cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP
882 results:
1. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced prostate cancer From Latin America: Challenges and Future Approaches.
Manneh R; Verson CA; Martin A; Delgado A; Isaacsson Velho PH; Manduley A; Tejado L; Rodríguez Y; Vargas C; Barata PC
JCO Precis Oncol; 2024 May; 8():e2300628. PubMed ID: 38748947
[TBL] [Abstract] [Full Text] [Related]
2. Homologous Recombination Repair Deficiency in Metastatic prostate cancer: New Therapeutic Opportunities.
Piombino C; Pipitone S; Tonni E; Mastrodomenico L; Oltrecolli M; Tchawa C; Matranga R; Roccabruna S; D'Agostino E; Pirola M; Bacchelli F; Baldessari C; Baschieri MC; Dominici M; Sabbatini R; Vitale MG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731844
[TBL] [Abstract] [Full Text] [Related]
3. Mechanism of single-stranded DNA annealing by RAD52-RPA complex.
Liang CC; Greenhough LA; Masino L; Maslen S; Bajrami I; Tuppi M; Skehel M; Taylor IA; West SC
Nature; 2024 May; 629(8012):697-703. PubMed ID: 38658755
[TBL] [Abstract] [Full Text] [Related]
4. [Drastic changes in the treatment of metastatic prostate cancer].
Thellenberg Karlsson C; Ståhl O
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38651316
[TBL] [Abstract] [Full Text] [Related]
5. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
[TBL] [Abstract] [Full Text] [Related]
6. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
[TBL] [Abstract] [Full Text] [Related]
7. cancer trend and radiotherapy utilization at a tertiary academic hospital in Malaysia.
Gan DEH; Bustam AZ
J Cancer Res Ther; 2024 Jan; 20(1):358-362. PubMed ID: 38554346
[TBL] [Abstract] [Full Text] [Related]
8. [Molecular testing of prostate cancer: timing, methods and consequences].
von Amsberg G; Paulsen FO
Aktuelle Urol; 2024 Apr; 55(2):123-133. PubMed ID: 38537659
[TBL] [Abstract] [Full Text] [Related]
9. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of prostate cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract] [Full Text] [Related]
10. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
11. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive prostate cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract] [Full Text] [Related]
12. Abrogation of KLF5 sensitizes
Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
[TBL] [Abstract] [Full Text] [Related]
13. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
14. Precision Medicine in Castration-Resistant prostate cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
[TBL] [Abstract] [Full Text] [Related]
15. Contemporary Systemic Therapy Intensification for prostate cancer: A Review for General Practitioners in Oncology.
Batra A; Glick D; Valdes M
Curr Oncol; 2024 Feb; 31(2):1047-1062. PubMed ID: 38392072
[TBL] [Abstract] [Full Text] [Related]
16. Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer.
Koguchi D; Tsumura H; Tabata KI; Shimura S; Satoh T; Ikeda M; Watanabe A; Yoshida T; Sasaki J; Matsumoto K; Iwamura M
Jpn J Clin Oncol; 2024 May; 54(5):569-576. PubMed ID: 38305663
[TBL] [Abstract] [Full Text] [Related]
17. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
[TBL] [Abstract] [Full Text] [Related]
18. Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.
Papadopoulou E; Rigas G; Fountzilas E; Boutis A; Giassas S; Mitsimponas N; Daliani D; Ziogas DC; Liontos M; Ramfidis V; Christophilakis C; Matthaios D; Floros T; Florou-Chatzigiannidou C; Agiannitopoulos K; Meintani A; Tsantikidi A; Katseli A; Potska K; Tsaousis G; Metaxa-Mariatou V; Nasioulas G
JCO Precis Oncol; 2024 Jan; 8():e2300332. PubMed ID: 38271656
[TBL] [Abstract] [Full Text] [Related]
19. Germline DNA Damage Response Gene Mutations in Localized prostate cancer.
Januskevicius T; Vaicekauskaite I; Sabaliauskaite R; Matulevicius A; Vezelis A; Ulys A; Jarmalaite S; Jankevicius F
Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256334
[No Abstract] [Full Text] [Related]
20. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
[Next]
